Desvenlafaxine: Independent Evidence on Depression, Side Effects & Withdrawal
Desvenlafaxine (Pristiq), venlafaxine’s metabolite, beats placebo for depression, but 50 mg is the ceiling, the UK never licensed it and withdrawal is a risk.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Desvenlafaxine (Pristiq), venlafaxine’s metabolite, beats placebo for depression, but 50 mg is the ceiling, the UK never licensed it and withdrawal is a risk.
Fluvoxamine (Faverin/Luvox) works for OCD and depression, but independent evidence ranks it mid-to-low for depression and flags major CYP1A2 drug interactions.
Propranolol for anxiety and stage fright: what independent reviews show, why the evidence is weak, the HSIB overdose warning, asthma risks and who funds it.
Hydroxyzine (Atarax, Ucerax) for anxiety: what the Cochrane review shows, the 2015 MHRA heart-rhythm dose limits, risks in older adults and who funds the evidence.
Clonazepam (Klonopin/Rivotril): what independent reviews show for panic and epilepsy, why 1 mg beat higher doses, boxed warnings, withdrawal and who funds it.
Buspirone (BuSpar): what independent reviews show for generalised anxiety, why it is slow and non-sedating, CYP3A4 interactions, safety and who funds the evidence.
Lorazepam (Ativan) is strongly evidenced for stopping status epilepticus but limited to 2–4 weeks for anxiety. Independent evidence on risks, withdrawal and funding.
Alprazolam (Xanax) eases panic and anxiety fast, but guidelines limit it to crises. Independent evidence on benefits, dependence, withdrawal, misuse and who funds it.
Independent review of nortriptyline: depression and late-life relapse evidence, off-label smoking cessation, weak nerve-pain data, overdose risk and blood levels.
Independent review of agomelatine (Valdoxan): small benefit over placebo, good tolerability, unpublished trials, liver-test rules and who funded the evidence.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.